Characterization of HIV-1 TAT peptide as an enhancer of HSV-TK/GCV cancer gene therapy

Cancer Gene Therapy

Volumn 15, Issue 5, 2008, Pages 303-314

  Rautsi, O ^a   Lehmusvaara, S ^a,b   Ketola, A ^a   Maatta A M ^a   Wahlfors, J ^a,c   Pellinen, R ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b UNIVERSITY OF TAMPERE   (Finland)

^c TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

HIV 1 TAT; HSV TK; Protein transduction domain; Suicide gene therapy

Indexed keywords

GANCICLOVIR; HERPES SIMPLEX VIRUS TYPE 1 THYMIDINE KINASE; THYMIDINE KINASE; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CELL DEATH; CONTROLLED STUDY; CYTOTOXICITY; GENE THERAPY; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; PRIORITY JOURNAL;

ANIMALS; ANTIVIRAL AGENTS; CELL DEATH; CHO CELLS; CRICETINAE; CRICETULUS; GANCICLOVIR; GENE THERAPY; HERPESVIRUS 1, HUMAN; HUMANS; NEOPLASMS; PEPTIDE FRAGMENTS; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; THYMIDINE KINASE;

CRICETULUS GRISEUS; HUMAN IMMUNODEFICIENCY VIRUS 1; SIMPLEXVIRUS;

EID: 41949088216     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2008.17     Document Type: Article

References (43)

1. Immonen A, Vapalahti M, Tyynela K, Hurskainen H, Sandmair A, Vanninen R et al. AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study. Mol Ther 2004; 10: 967-972.
2. Sandmair AM, Loimas S, Puranen P, Immonen A, Kossila M, Puranen M et al. Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. Hum Gene Ther 2000; 11: 2197-2205.
3. Moolten FL. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 1986; 46: 5276-5281.
4. Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM. In vivo gene transfer with retroviral vectorproducer cells for treatment of experimental brain tumors. Science 1992; 256: 1550-1552.
5. Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL et al. The 'bystander effect': tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993; 53: 5274-5283.
6. Touraine RL, Ishii-Morita H, Ramsey WJ, Blaese RM. The bystander effect in the HSVtk/ganciclovir system and its relationship to gap junctional communication. Gene Ther 1998; 5: 1705-1711.
7. Dietz GP, Bahr M. Delivery of bioactive molecules into the cell: the Trojan horse approach. Mol Cell Neurosci 2004; 27: 85-131.
8. Gratton JP, Yu J, Griffith JW, Babbitt RW, Scotland RS, Hickey R et al. Cell-permeable peptides improve cellular uptake and therapeutic gene delivery of replication-deficient viruses in cells and in vivo. Nat Med 2003; 9: 357-362.
9. Lehmusvaara S, Rautsi O, Hakkarainen T, Wahifors J. Utility of cell-permeable peptides for enhancement of virus-mediated gene transfer to human tumor cells. Biotechniques 2006; 40: 573-574, 576.
10. Torchilin VP, Levchenko TS, Rammohan R, Volodina N, Papahadjopoulos- Sternberg B, D'Souza GG. Cell transfection in vitro and in vivo with nontoxic TAT peptide-liposome-DNA complexes. Proc Natl Acad Sci USA 2003; 100: 1972-1977.
11. Console S, Marty C, Garcia-Echeverria C, Schwendener R, Ballmer-Hofer K. Antennapedia and HIV transactivator of transcription (TAT) 'protein transduction domains' promote endocytosis of high molecular weight cargo upon binding to cell surface glycosaminoglycans. J Biol Chem 2003; 278: 35109-35114.
12. Richard JP, Melikov K, Brooks H, Prevot P, Lebleu B, Chernomordik LV. Cellular uptake of unconjugated TAT peptide involves clathrin-dependent endocytosis and heparan sulfate receptors. J Biol Chem 2005; 280: 15300-15306.
13. Vives E, Brodin P, Lebleu B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem 1997; 272: 16010-16017.
14. Ferrari A, Pellegrini V, Arcangeli C, Fittipaldi A, Giacca M, Beltram F. Caveolae-mediated internalization of extracellular HIV-1 tat fusion proteins visualized in real time. Mol Ther 2003; 8: 284-294.
15. Wadia JS, Stan RV, Dowdy SF. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat Med 2004; 10: 310-315.
16. Merilainen O, Hakkarainen T, Wahlfors T, Pellinen R, Wahlfors J. HIV-1 TAT protein transduction domain mediates enhancement of enzyme prodrug cancer gene therapy in vitro: a study with TAT-TK-GFPtriple fusion construct. Int J Oncol 2005; 27: 203-208.
17. Esko JD, Weinke JL, Taylor WH, Ekborg G, Roden L, Anantharamaiah G et al. Inhibition of chondroitin and heparan sulfate biosynthesis in Chinese hamster ovary cell mutants defective in galactosyltransferase I. J Biol Chem 1987; 262: 12189-12195.
18. Lidholt K, Weinke JL, Kiser CS, Lugemwa FN, Bame KJ, Cheifetz S et al. A single mutation affects both N-acetylglucosaminyltransferase and glucuronosyltransferase activities in a Chinese hamster ovary cell mutant defective in heparan sulfate biosynthesis. Proc Natl Acad Sci USA 1992; 89: 2267-2271.
19. Loimas S, Wahlfors J, Janne J. Herpes simplex virus thymidine kinase-green fluorescent protein fusion gene: new tool for gene transfer studies and gene therapy. Biotechniques 1998; 24: 614-618.
20. Pellinen R, Hakkarainen T, Wahlfors T, Tulimaki K, Ketola A, Tenhunen A et al. Cancer cells as targets for lentivirus-mediated gene transfer and gene therapy. Int J Oncol 2004; 25: 1753-1762.
21. Rubartelli A, Poggi A, Sitia R, Zocchi MR. HIV-I Tat: a polypeptide for all seasons. Immunol Today 1998; 19: 543-545.
22. Chauhan A, Tikoo A, Kapur AK, Singh M. The taming of the cell penetrating domain of the HIV Tat: myths and realities. J Control Release 2007; 117: 148-162.
23. Jones SW, Christison R, Bundell K, Voyce CJ, Brockbank SM, Newham P et al. Characterisation of cell-penetrating peptide-mediated peptide delivery. Br J Pharmacol 2005; 145: 1093-1102.
24. Cashman SM, Morris DJ, Kumar-Singh R. Evidence of protein transduction but not intercellular transport by proteins fused to HIV tat in retinal cell culture and in vivo. Mol Ther 2003; 8: 130-142.
25. Becker-Hapak M, McAllister SS, Dowdy SF. TAT-mediated protein transduction into mammalian cells. Methods 2001; 24: 247-256.
26. Nagahara H, Vocero-Akbani AM, Snyder EL, Ho A, Latham DG, Lissy NA et al. Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration. Nat Med 1998; 4: 1449-1452.
27. Leifert JA, Harkins S, Whitton JL. Full-length proteins attached to the HIV tat protein transduction domain are neither transduced between cells, nor exhibit enhanced immunogenicity. Gene Ther 2002; 9: 1422-1428.
28. Xia H, Mao Q, Davidson BL. The HIV Tat protein transduction domain improves the biodistribution of beta-glucuronidase expressed from recombinant viral vectors. Nat Biotechnol 2001; 19: 640-644.
29. Elliger SS, Elliger CA, Lang C, Watson GL. Enhanced secretion and uptake of beta-glucuronidase improves adeno-associated viral-mediated gene therapy of mucopolysaccharidosis type VII mice. Mol Ther 2002; 5: 617-626.
30. Thust R, Tomicic M, Klocking R, Voutilainen N, Wutzler P, Kaina B. Comparison of the genotoxic and apoptosisinducing properties of ganciclovir and penciclovir in Chinese hamster ovary cells transfected with the thymidine kinase gene of herpes simplex virus-1: implications for gene therapeutic approaches. Cancer Gene Ther 2000; 7: 107-117.
31. Tomicic MT, Thust R, Kaina B. Ganciclovir-induced apoptosis in HSV-1 thymidine kinase expressing cells: critical role of DNA breaks, Bcl-2 decline and caspase-9 activation. Oncogene 2002; 21: 2141-2153.
32. Tasciotti E, Zoppe M, Giacca M. Transcellular transfer of active HSV-1 thymidine kinase mediated by an 11-aminoacid peptide from HIV-1 Tat. Cancer Gene Ther 2003; 10: 64-74.
33. Tasciotti E, Giacca M. Fusion of the human immunodeficiency virus type 1 tat protein transduction domain to thymidine kinase increases bystander effect and induces enhanced tumor killing in vivo. Hum Gene Ther 2005; 16: 1389-1403.
34. Cascante A, Huch M, Rodriguez LG, Gonzalez JR, Costantini L, Fillat C. Tat8-TK/GCV suicide gene therapy induces pancreatic tumor regression in vivo. Hum Gene Ther 2005; 16: 1377-1388.
35. Vilcek J, Sen GC. Interferons and other cytokines. In: Fields B, Knipe D, Howley P(eds). Fundamental Virology, 3rd edn. Lippincott-Raven Publishers: Philadelphia, 1996, pp 341-365.
36. McMillan NA, Chun RF, Siderovski DP, Galabru J, Toone WM, Samuel CE et al. HIV-1 Tat directly interacts with the interferon-induced, double-stranded RNA-dependent kinase, PKR. Virology 1995; 213: 413-424.
37. Rautsi O, Lehmusvaara S, Salonen T, Hakkinen K, Sillanpaa M, Hakkarainen T et al. Type I interferon response against viral and non-viral gene transfer in human tumor and primary cell lines. J Gene Med 2007; 9: 122-135.
38. Mani K, Sandgren S, Lilja J, Cheng F, Svensson K, Persson L et al. HIV-Tat protein transduction domain specifically attenuates growth of polyamine deprived tumor cells. Mol Cancer Ther 2007; 6: 782-788.
39. Belting M, Persson S, Fransson LA. Proteoglycan involvement in polyamine uptake. Biochem J 1999; 338(Part 2): 317-323.
40. Mi MY, Zhang J, He Y. Inhibition of HIV derived lentiviral production by TAR RNA binding domain of TAT protein. Retrovirology 2005; 2: 71.
41. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D et al. A third-generation lentivirus vector with a conditional packaging system. J Virol 1998; 72: 8463-8471.
42. Zufferey R, Dull T, Mandel RJ, Bukovsky A, Quiroz D, Naldini L et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 1998; 72: 9873-9880.
43. Luciw P. Human immunodeficiency viruses and their replication. In: Fields B, Knipe D, Howley P (eds). Fundamental Virology, 3rd edn. Lippincott- Raven Publishers: Philadelphia, 1996, pp 845-916.